JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Our results indicate that co-treatment with imatinib and JAK2 inhibitors may have the potential for targeting residual CML cells by enhancing imatinib efficiency and reducing cytokine production by stromal cells.